<DOC>
	<DOCNO>NCT00251433</DOCNO>
	<brief_summary>This two-part study ( Phase I/Phase II ) . Part I design find optimal ( best ) dose GW572016 , docetaxel , trastuzumab give together , Part II design evaluate tumor response rate ( shrinkage lack growth ) patient receive three drug compare patient receive docetaxel trastuzumab .</brief_summary>
	<brief_title>GW572016 With Docetaxel Trastuzumab Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Subjects must 18 year age . Criteria female subject : Nonchildbearing potential ( i.e. , woman function ovary current document tubal ligation hysterectomy , woman post menopausal ) ; Childbearing potential ( i.e. , woman function ovary document impairment oviductal uterine function would cause sterility . ) This category include woman oligomenorrhoea ( severe ) , woman perimenopausal , young woman begin menstruate . These subject must negative serum pregnancy test screen agree one following : Complete abstinence intercourse 2 week prior administration first dose study medication 28 day final dose study medication ; Consistent correct use one follow acceptable method birth control : male partner sterile prior female subject 's entry study sole sexual partner female subject ; implant levonorgestrel ; injectable progestogen ; intrauterine device ( IUD ) document failure rate le 1 % per year ; oral contraceptive ( either combine progestogen ) ; barrier method , include diaphragm condom spermicide . Subjects must ECOG Performance Status 0 1 . Subjects must histologically cytologicallyconfirmed invasive breast cancer Stage IV disease . Subjects must measurable lesion ( ) accord RECIST criterion phase II , however phase I subject evaluable disease allow ( include patient bone lesion disease ) . Prior enrolment Phase I part study , subject must documentation ErbB2 overexpression via IHC3+ FISH+ test . Prior enrolment Phase II part study , subject must ErbB2 overexpression confirm central laboratory , Subjects stable CNS metastasis leptomeningeal involvement eligible take oral steroid enzymeinducing anticonvulsant . Subjects CNS disease allow . Subjects receive prior radiotherapy must complete radiotherapy treatment least 4 week enrolment recover treatmentrelated toxicity . Subjects must new archive tumour tissue available prior study entry evaluate level relevant biomarkers . Subjects must cardiac ejection fraction within institutional range normal measure Multigated Acquisition ( MUGA ) scan echocardiogram ( ECHO ) . Subjects must adequate haematological , hepatic , renal function . Haemoglobin ≥9gm/dL Absolute granulocyte count ≥1500/mm³ ( 1.5 x 10^9/L ) Platelets ≥75,000/mm³ ( 75 x 10^9/L ) Total bilirubin ≤1.5mg/dL Both ALT AST ≤1.5 time upper limit normal range ( ULN ) alkaline phosphatase ≤2.5 time ULN ( See Taxotere Data Sheet ) Serum creatinine ≤ 2.0mg/dL calculated creatinine clearance ( CrCl ) ≥40mL/min accord formula Cockcroft Gault Subjects receive taxane part adjuvant neoadjuvant therapy eligible progression disease 6 month completion treatment . Subjects receive prior ErbB inhibitor adjuvant set allow , diseasefree interval least 6 month must demonstrate end therapy . Subject peripheral neuropathy grade 2 high ; Subject prior systemic therapy ( except one line hormonal therapy ) metastatic disease . Also , subject prior chemotherapy adjuvant neoadjuvant set anthracycline anthracenedionecontaining regimen cumulative dos ≥360mg/m² doxorubicin , ≥720mg/m² epirubicin , ≥72mg/m² mitoxantrone ; Subjects prior systemic investigational drug within past 30 day topical investigational drug within past 7 day ; Subjects uncontrolled symptomatic angina , arrhythmia , congestive heart failure ; Subjects know immediate delay hypersensitivity untoward reaction docetaxel , trastuzumab , related compound , drug chemically relate lapatinib . These include aminoquinazolines , gefitinib ( Iressa ) , erlotinib ( Tarceva ) , chemicallyrelated compound . Subjects take prohibited medication Subject neither affiliated , beneficiary social security category ( For France )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ErbB1</keyword>
	<keyword>ErbB2</keyword>
	<keyword>trastuzumab ( Herceptin )</keyword>
	<keyword>lapatinib</keyword>
	<keyword>Stage IV breast cancer</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>overexpression ErbB2 receptor</keyword>
	<keyword>docetaxel ( Taxotere )</keyword>
</DOC>